10.325  0.015 (0.15%)		11-04 16:00
Open: 10.3283 High: 10.3283 Volume: 201,123		Pre. Close: 10.31 Low: 10.31 Market Cap: 346(M)

Short term
Mid term
Targets	6-month :	12.08	1-year :	14.11
Resists	First :	10.35	Second :	12.08
Pivot price	10.31
Supports	First :	10.29	Second :	10.26
MAs	MA(5) :	10.31	MA(20) :	10.3
	MA(100) :	10.25	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	57.9	D(3) :	62.3
RSI	RSI(14): 57.6
52-week	High :	10.35	Low :	9.96

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DMAA ] has closed below upper band by 20.1%. Bollinger Bands are 18.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.33 - 10.39	10.39 - 10.45
Low:	10.14 - 10.21	10.21 - 10.28
Close:	10.19 - 10.3	10.3 - 10.43

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Thu, 02 Oct 2025
Drugs Made In America Acquisition II Corp. completes $500 million IPO and private placement - Investing.com

Fri, 26 Sep 2025
$500 Million SPAC IPO: Drugs Made In America Acquisition II Launches with Healthcare Focus on Nasdaq - Stock Titan

Thu, 25 Sep 2025
Drugs Made In America Acquisition II prices $500 million IPO at $10 per unit - Investing.com

Thu, 25 Sep 2025
$500 Million SPAC IPO: Drugs Made In America II Prices 50 Million Units with Rights Structure - Stock Titan

Sat, 16 Aug 2025
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company - Yahoo Finance

Mon, 31 Mar 2025
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	34 (M)
Shares Float	23 (M)
Held by Insiders	26.7 (%)
Held by Institutions	63.7 (%)
Shares Short	52 (K)
Shares Short P.Month	51 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.21
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-49.17
Price to Sales	0
Price to Cash Flow	-1171.97

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.